Fight Over "Pink Pill" Raises Sexism Questions


Around 1,000 women participated in the clinical trials. According to Sprout Pharmaceutical’s results, on average, women taking Flibanserin doubled their number of so-called “satisfying sexual events” with taking the drug, and reported a 50 percent increase in sexual desire. But about 15 percent of those women in the clinical trials dropped out because of side effects, including sleepiness, dizziness and anxiety, which Flibanserin proponents point out seem mild compared to the side effects listed in the now iconic Viagra commercials, such as nausea, diarrhea and the risk of erections lasting over four hours.

The FDA last rejected Flibanserin in December 2013, though Whitehead and Sprout Pharmaceuticals are appealing the FDA’s decision.


Read More